Nanox Targets Over 100 Imaging Deployments in 2025 as Revenue Grows and Losses Narrow Marginally
Steady Revenue Growth Driven by Teleradiology and Commercial Partnerships
Nanox's latest third-quarter results show a company intent on accelerating commercialization and market reach. For Q3 2025, the Israeli medical imaging innovator posted $3.4 million in revenue—a rise from $3.0 million in the same period last year. The majority of this improvement was driven by increased customer retention and volume in teleradiology services, underscoring the company’s strategic focus on scalable solutions for imaging and diagnostics.
Progress in Clinical Deployment and Market Expansion Remains the Key Story
Perhaps the most critical takeaway: Nanox remains on track to meet its target of deploying more than 100 imaging systems by the end of 2025. The company continued to advance clinical partnerships, recently adding prominent names such as Cedars-Sinai in Los Angeles and Olympe Imagerie in Paris as new trial sites. Nanox’s move into Europe also gained traction through distribution deals with major regional partners EXRAY and Althea France SARL.
Financial Overview: Higher Revenue, Controlled Operating Expenses, Ongoing Losses
The net loss for Q3 2025 stood at $13.7 million—just above the prior year's loss of $13.6 million, reflecting significant ongoing investment in R&D and commercialization. The company saw notable improvement in gross profit margin from its core teleradiology segment (25% GAAP and 43% non-GAAP), offset by persistent losses in AI solutions and system sales as deployment scales up. Cash resources declined to $55.5 million from $83.2 million at year-end 2024, as Nanox deployed capital to grow its platform and acquired Vaso Healthcare IT to bolster its AI offerings.
| Key Metric | Q3 2025 | Q3 2024 |
|---|---|---|
| Total Revenue ($M) | 3.45 | 3.03 |
| Net Loss ($M) | 13.68 | 13.64 |
| Teleradiology Revenue ($M) | 3.10 | 2.60 |
| Teleradiology Gross Profit Margin (GAAP) | 25% | 13% |
| Teleradiology Gross Profit Margin (Non-GAAP) | 43% | 35% |
| Cash & Equivalents ($M) | 55.5 | 83.2* |
| Shares Outstanding (M) | 65.4 | 63.8* |
*2024 year-end values
Acquisitions and AI Solutions Signal a Strategic Shift
During the quarter, Nanox closed its acquisition of Vaso Healthcare IT and struck several global collaborations aimed at driving both the deployment of Nanox.ARC and expanding AI imaging solutions. Management emphasizes improved operational efficiency and expanded clinical and commercial pipelines as critical levers for sustainable long-term growth.
Outlook: 2026 Revenue Guidance and Continued Capital Deployment
Looking forward, Nanox projects 2026 revenues of $35 million—an ambitious leap that reflects expectations for scaling both deployments and recurring teleradiology and AI revenues. Management’s confidence is buttressed by a cash position of $55.5 million and the controlled sale of 1.4 million ordinary shares in Q3, raising net proceeds of $5.7 million. Still, negative operating cash flows ($30.4 million outflow in the reported period) and the pressure of ongoing losses point to a need for careful execution as growth accelerates.
Key Takeaway: Momentum Builds but Risks Remain
While revenue momentum and growing margins in teleradiology are positive signs, Nanox remains in an investment-heavy phase, with scaling losses and significant R&D and market expansion spending. The company's success hinges on hitting deployment targets and capturing meaningful recurring revenue from its expanding global partnerships. Investors should monitor the pace of system deployments and cash burn in upcoming quarters to gauge how quickly Nanox can approach profitability as it pursues its vision for global healthcare transformation.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI